CONSUMER NEWS    RECALLS    COMPLAINT FORM    SCAM ALERTS  


Complain about a product or service

Small Claims Guide | Class Actions | Lemon Law | FAQ | Resources | Newsletters | Spanish
Automotive    Education    Electronics    Family    Finance    Health    Homeowners    Shopping    Travel   
NEWS   Latest |  Archives |  Auto |  Cells, etc. |  Computers |  Financial |  Health |  Homeowners |  Parents |  Privacy |  Scams |  Seniors |  Travel

Interest Builds in New Weight Loss Drug, Acomplia





May 6, 2005
A report in The Lancet is stirring heightened interest in the new weight-loss drug Acomplia (rimonabant), expected to be available in the U.S. next year. The report was based on one-year results from the RIO-Europe clinical trial, which showed that Acomplia could substantially reduce the weight, waist circumference and risk factors for heart disease in obese people.

Acomplia
EFF Files Suit to Protect Journalist From Drug Company Intimidation
Interest Builds in New Weight Loss Drug, Acomplia
Sanofi-Aventis Tries to Muzzle Web Newsletter

Acomplia has been hailed by some doctors on the basis of interim study results as potentially a major breakthrough in treating obesity, according to the Acomplia Report, a Web newsletter.

Other once-promising anti-obesity drugs like Xenical, Meridia (Reductil in Europe), and phentermine, however, have proven to have troublesome side effects, disappointing millions of dieters, the report noted.

Another diet drug under development, Axokine, also has been reported to have a high rate of side effects in clinical trials.

In the Lancet article, Dr. Luc Van Gaal of University Hospital in Antwerp, Belgium, the lead researcher in the RIO-Europe trial, said treatment with the drug over one year led to "sustained, clinically meaningful weight loss, reduction in waist circumference, and associated improvements in several cardiovascular and metabolic risk factors."

In an accompanying editorial, Drs. Uberto Pagotto and Renato Pasquali of Sant Orsola-Malpighi General Hospital, Bologna, Italy, support the assertion, writing: "A new pharmacological treatment to tackle obesity, and alterations of metabolic and lipid profiles that are often associated, could now be close to clinical practice."

"These data, and those from the other ongoing clinical trials with rimonabant, might presumably help us to better tackle obesity and related metabolic and cardiovascular disease."



Report Your Experience
If you've had a bad experience -- or a good one -- with a consumer product or service, we'd like to hear about it. All complaints are reviewed by class action attorneys and are considered for publication on our site. Knowledge is power! Help spread the word. File your consumer report now.


Consumer News

August 29 2008

Recent Recalls & Safety Alerts



FREE CONSUMER NEWSLETTERS

The Daily Consumer
Afternoons M-F

Sign up now!


Consumer News & Alerts
Every Sunday

Sign up now!


Knowledge is free.
Knowledge is power.



Back to the top |

Advertisement


Home | Complaint Form | News | Recalls | FAQ |
Consumer Resources | Small Claims Guide | Lemon Law | Newsletter | Contact Us
Advertise With Us | Testimonials | Newsroom | RSS Feeds |


Terms of Use Your use of this site constitutes acceptance of the Terms of Use

Advertisements on this site are placed and controlled by outside advertising networks. ConsumerAffairs.com does not evaluate or endorse the products and services advertised. See the FAQ for more information.

Company Response Welcome If complaints about your company appear on our site, we welcome your response. Please see the Response Form for more information.

For more information, see the FAQ and privacy policy. The information on this Web site is general in nature and is not intended as a substitute for competent legal advice.  ConsumerAffairs.com Inc. makes no representation as to the accuracy of the information herein provided and assumes no liability for any damages or loss arising from the use thereof. 

Copyright © 2003-2008 ConsumerAffairs.com Inc.  All Rights Reserved.    The contents of this site may not be republished, reprinted, rewritten or recirculated without written permission.